1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 14 DECEMBER 2015

Cancer Drug News 14 DECEMBER 2015

  • December 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Leveraging Long-Term Data For Sustained Commercial Success
Industry Brief - Novartis To Begin Regulatory Submissions For Midostaurin In 2016
Industry Brief - Seattle Genetics To Move Novel ADC Into Phase III
Industry Brief - Genentech Reports Positive Pivotal Results From Venetoclax Phase II CLL Study
Industry Brief - Qinprezo Submitted To EMA For AML
Industry Brief - Milestone Triggered As FDA Approves Bendeka For CLL/NHL
Industry Trend Analysis - AbbVie Unlocking Imbruvica's Value
Industry Brief - Iclusig Phase III Trial Started In Second-Line Chronic Phase CML
Industry Brief - Amgen/Merck Enter Cancer Immunotherapy Collaboration
Industry Brief - Celgene/Astrazeneca Expand Immuno-Oncology Commitment
Industry Trend Analysis - Genomic Data Will Limit MM Market Size
Industry Brief - Lilly/Merck Expand Immuno-Oncology Collaboration
Industry Trend Analysis - Pfizer's Long-Term Oncology Position Not Limited By Xalkori
Industry Brief - Alecensa Launched In Japan
Industry Brief - HMP Initiates Fruquintinib Phase III Trial In NSCLC
Industry Brief - EMA Grants Orphan Drug Designation To Debio 1143
Industry Brief - Merck KGaA Initiates Two Phase III Studies Of Avelumab
Industry Brief - Merck KGaA Not to Pursue Evofosfamide Further In STS/PC
Industry Brief - XBiotech's Xilonix Meets Primary Endpoint In Phase III CRC Study
Industry Brief - Entrectinib Receives EU ODD For Neuroblastoma

Table Of Contents

Cancer Drug News 14 DECEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.